Navigation Links
AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
Date:6/10/2013

CONSHOHOCKEN, Pa., June 10, 2013 /PRNewswire/ -- ePharmaSolutions, a leading clinical services and eClinical solutions provider, has signed a deal with AstraZeneca Neuroscience Innovative Medicines (AZ NS iMed), to provide IT solutions that will enable the iMed to share and manage complex data on a common portal with clinical trial investigators and other external partners.  The ePharmaSolutions integrated clinical trial portal will also feature an electronic trial master file (eTMF) solution and cloud technology for sharing documents securely. Initially, the ePharmaSolutions technology will be used to manage three separate neuroscience clinical trials.

AstraZeneca's Neuroscience iMed is a unique model in the pharma industry – a core of about 40 neuroscientists managing a portfolio of drug discovery and development projects solely with external partners.  Since it was created just over a year ago, the iMed has strived to implement innovative technologies that enable it to work seamlessly – quickly and efficiently – with investigators, contract research organizations, academic researchers and regulatory authorities.  "A key strategy for our business is crafted around relationship building and leveraging innovative solutions for data sharing with collaborators," said Steven Leventer, PhD, VP, AZ NS iMed. "The capabilities brought to the table by ePharmaSolutions are aimed at enabling the AZ NS iMed to ramp up our clinical trial sites more quickly and efficiently."

"We are very pleased to have been selected by the AZ NS iMed team for this collaboration," adds Lance Converse, founder and CEO of ePharmaSolutions. "Our integrated trial portal, document exchange and eTMF platform will play a pivotal role in supporting the study teams as well as the investigator sites."

About ePharmaSolutions

ePharmaSolutions is a leading provider of eClinical solutions that help improve the way trial sites are selected, trained, activated and managed to exceed enrollment goals. ePharmaSolutions has won multiple Bio-IT World Award for best clinical trial technology and has activated and trained more than 300,000 clinical researchers in 130 countries for the top 20 pharmaceutical companies and CROs in the world. ePharmaSolutions is headquartered in Philadelphia with offices in Slough, UK. For more information, visit www.epharmasolutions.com or email info@epharmasolutions.com

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.


'/>"/>
SOURCE ePharmaSolutions
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
2. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
3. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
4. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
5. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
6. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
7. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
8. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
9. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
10. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
11. AstraZeneca Acquires Neuroscience Assets From Link Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... NEW YORK , December 7, 2016 ... Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals ... DNAI ), and AveXis Inc. (NASDAQ: ... Biotechnology Sector Index fell roughly 37% to reach a level ... While it is down by approximately 14% for the year, ...
(Date:12/6/2016)... BROOKLYN, N.Y. , Dec. 6, 2016  Licenders is bringing ... . This new location in Park Slope at 203 13 th ... Brooklyn clientele. "Our goal is ... Our treatment plans are designed to get children right back to ... products are 100% all natural and safe for the whole family," ...
(Date:12/6/2016)... 6, 2016 Diabetes & Obesity Drug Development ... obesity disease cluster is currently dominated by therapeutics indicated ... diabetes mellitus (T2DM), and the majority of the pipeline, ... is attributable to these indications. While products indicated for ... there are a large number of these products in ...
Breaking Medicine Technology:
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware that ... One major study analyzing heart attacks among 138,602 people recorded a 35% higher number ... We would all agree of course–no time of year is a good time for ...
(Date:12/7/2016)... ... ... “The Road To Restoration”: an informative and enlightening book for those who believe ... hands. “The Road To Restoration” is the creation of published author, Thomas Fitzhugh Sheets, ... that you could reach out for, and grab, on the old carousels. If ...
(Date:12/7/2016)... Soquel, Caloifornia (PRWEB) , ... December 07, 2016 ... ... to present the fifth annual Business Architecture Innovation Summit in Reston, VA on ... the world who will share a range of experiences from a cross-section of ...
(Date:12/6/2016)... ... 2016 , ... The International Vaccine Institute (IVI) and GeneOne ... Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine development ... in the event of a future outbreak. , IVI and GeneOne held a ...
Breaking Medicine News(10 mins):